InMed Pharmaceuticals Provides Update On INM-089 In The Treatment Of Dry Age-Related Macular Degeneration; Small Molecule Drug Acting As A Preferential Signaling Ligand For CB1/CB2
InMed Pharmaceuticals Provides Update On INM-089 In The Treatment Of Dry Age-Related Macular Degeneration; Small Molecule Drug Acting As A Preferential Signaling Ligand For CB1/CB2
InMed Pharmicals 提供 INM-089 治療乾性年齡相關黃斑變性的最新情況；小分子藥物作爲 CB1/CB2 的優先信號配體
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
InMed 提供 INM-089 治療乾性年齡相關性黃斑變性的最新情況
● Small molecule drug acting as a preferential signaling ligand for CB1/CB2● Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model
● 小分子藥物作爲 CB1/CB2 的優先信號配體● 改善體內臨床前疾病模型中的視網膜色素上皮完整性、神經保護和光感受器改善
Vancouver, BC – April 16, 2024 – InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced additional preclinical data for INM-089 further demonstrating positive pharmacological effects targeting dry Age-Related Macular Degeneration ("AMD").
不列顛哥倫比亞省溫哥華——2024年4月16日——稀有大麻素和專有大麻素類似物研究、開發、製造和商業化的領導者InMed製藥公司（“InMed” 或 “公司”）（納斯達克股票代碼：INM）今天公佈了更多的 INM-089 臨床前數據，進一步顯示了針對乾性年齡相關性黃斑變性（“AMD”）的積極藥理作用。
Dr. Eric Hsu, SVP of Preclinical Research and Development, stated, "We are very...
臨床前研究與開發高級副總裁...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。